Moderna has submitted a revised approach to streamline approval based on age-specific indications. ・The company proposed a ...

These ten large-cap stocks were top performers last week. Are they a part of your portfolio? First Majestic Silver Corp. AG gained 25.23% this week after the company reported better-than-expected ...

Following a Type A meeting, the FDA's Center for Biologics Evaluation and Research has notified Moderna that its biologics ...

Moderna announced the change Wednesday, about a week after revealing that the FDA’s vaccine chief was refusing to review the ...

CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an update on regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, for ...

Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: ...

Moderna, Inc. (NASDAQ:MRNA) is one of the stocks in focus on Jim Cramer’s game plan. Cramer finished his game plan with the stock, as he commented: Finally, Friday, we’re going to hear from Moderna, ...

Moderna (MRNA) stock is on the rise after the U.S. Food & Drug Administration (FDA) accepted the company's flu vaccine ...

Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ...

Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna ...

Moderna Inc. (NASDAQ:MRNA) has announced plans to reduce its global workforce by approximately 10% by the end of the year due to decreasing COVID-19 vaccine sales and market uncertainty. Moderna CEO ...

Moderna beat fourth-quarter sales expectations and forecast growth for 2026, but an FDA refusal on its flu vaccine raises new ...